Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Galantamine Hydrobromide

FDA-approved product (tablet, oral), marketed as Galantamine Hydrobromide, Razadyne, Razadyne Er.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Galantamine Hydrobromide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alzheimer disease
  • Dementia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anticholinesterases
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae89.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 1 of 1 lab record
Open Galantamine Hydrobromide in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Galantamine Hydrobromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease

    NCT00338117 · start 1995-08

    Registered record
    Registry ID
    NCT00338117
    Conditions
    Alzheimer's Disease; Dementia
    Interventions
    Galantamine hydrobromide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-08
    Completion
    1997-05
    Enrolment
    554

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease; Dementia
    InterventionGalantamine hydrobromide
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of Galantamine in the Treatment of Alzheimer's Disease

    NCT00000172

    Registered record
    Registry ID
    NCT00000172
    Conditions
    Alzheimer Disease
    Interventions
    Galantamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionGalantamine
    PhasePhase 3
    Registry statusCompleted

  • Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder

    NCT00181636

    Registered record
    Registry ID
    NCT00181636
    Conditions
    Bipolar Disorder
    Interventions
    Galantamine-CR
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2006-10
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionGalantamine-CR
    PhaseNot applicable
    Registry statusCompleted

  • A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.

    NCT00309725

    Registered record
    Registry ID
    NCT00309725
    Conditions
    Alzheimer's Disease
    Interventions
    galantamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1999-10
    Enrolment
    139

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    Interventiongalantamine
    PhasePhase 3
    Registry statusCompleted

  • The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD)

    NCT00626613

    Registered record
    Registry ID
    NCT00626613
    Conditions
    Dementia; Alzheimer's Disease
    Interventions
    Risperdal,reminyl
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Alzheimer's Disease
    InterventionRisperdal,reminyl
    PhasePhase 4
    Registry statusUnknown